Cart
sales@molnova.com
PD173074
CAS No. 219580-11-7
PD173074( PD173074 | PD 173074 | PD-173074 )
Catalog No. M13497 CAS No. 219580-11-7
PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 51 | In Stock |
|
| 5MG | 34 | In Stock |
|
| 10MG | 49 | In Stock |
|
| 25MG | 86 | In Stock |
|
| 50MG | 133 | In Stock |
|
| 100MG | 217 | In Stock |
|
| 200MG | 384 | In Stock |
|
| 500MG | 641 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePD173074
-
NoteResearch use only, not for human use.
-
Brief DescriptionPD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
-
DescriptionPD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
-
In Vitro——
-
In Vivo——
-
SynonymsPD173074 | PD 173074 | PD-173074
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR| FGFR1| Insulin Receptor| c-Src| VEGFR2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number219580-11-7
-
Formula Weight523.67
-
Molecular FormulaC28H41N7O3
-
Purity>98% (HPLC)
-
SolubilityEthanol: 100 mg/mL (190.95 mM); DMSO: 100 mg/mL (190.95 mM)
-
SMILESO=C(NC1=NC2=NC(NCCCCN(CC)CC)=NC=C2C=C1C3=CC(OC)=CC(OC)=C3)NC(C)(C)C
-
Chemical Name1-(tert-butyl)-3-(2-((4-(diethylamino)butyl)amino)-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl)urea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Mohammadi M, et al. EMBO J, 1998, 17(20), 5896-5904.
molnova catalog
related products
-
AZ7550
AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
-
HER2/neu (654-662) G...
Affibody (affibody) ligands that are specific for the extracellular domain of human epidermal growth factor receptor 2 (HER2/neu) have been selected by phage display technology from a combinatorial protein library based on the 58 amino acid residue staphylococcal protein A-derived Z domain.
-
Lapatinib ditosylate...
Lapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y.
